SCHEMBL5285256

SCHEMBL5285256

O=C(O)CC(c1ccccc1)n1cnc2ccc(NC(=O)C3CCCO3)cc21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 4/20 0.48
HPGD P15428 11/20 0.47
ALDH1A1 P00352 10/20 0.47
NPC1 O15118 5/20 0.47
RAB9A P51151 4/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
KDM4E B2RXH2 3/20 0.47
POLB P06746 3/20 0.46
MAPT P10636 3/20 0.46
LMNA P02545 2/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
HTT P42858 1/20 0.46
HSD17B10 Q99714 3/20 0.45
PKM P14618 1/20 0.43
MAP4K4 O95819 1/20 0.43
TDP1 Q9NUW8 1/20 0.42
GAA P10253 1/20 0.42
NPY2R P49146 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2299775 0.80 HTR1E (0.53) TP53ALDH1A1MAPTLMNAMEN1
SCHEMBL5302265 0.80 EPHX2 (0.48) HPGDALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL2292264 0.80 NPC1 (0.44) TP53ALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL5280316 0.80 GHSR (0.47) ALDH1A1NPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL5284712 0.80 POLB (0.43) SMN1; SMN2KDM4EPOLBMEN1KMT2A
SCHEMBL2299946 0.79 KMT2A (0.44) TP53HPGDALDH1A1SMN1; SMN2MAPT
SCHEMBL2292578 0.79 KDM4E (0.44) TP53ALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL2294478 0.79 NPC1 (0.48) TP53NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL2294191 0.78 NPC1 (0.38) NPC1RAB9ASMN1; SMN2MAPTLMNA
SCHEMBL5301651 0.78 THRB (0.39) HPGDALDH1A1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1828144-A2 INTEGRIN ANTAGONISTS USEFUL AS ANTICANCER AGENTS OSI Pharmaceuticals, Inc. (US) 2007-09-05 EP claimed
WO-2006053342-A2 INTEGRIN ANTAGONISTS USEFUL AS ANTICANCER AGENTS OSI PHARMACEUTICALS, INC. (US) 2006-05-18 WO claimed